Iradimed 2025 Q1 Earnings Strong Growth as Net Income Rises 13.3%

Iradimed Corporation (IRMD) released its fiscal 2025 Q1 earnings on May 5, 2025. The company reported a notable increase in both revenue and net income compared to the previous year. Iradimed’s financial results surpassed market expectations, with its robust performance driven by strong product demand and operational excellence. The company maintained its full-year guidance, projecting continued growth in revenue and earnings. Analysts had anticipated strong results, and the company's performance aligned with these projections, suggesting confidence in its future outlook.

Revenue

Iradimed's total revenue for Q1 2025 was $19.51 million, a 10.9% increase from the $17.60 million reported in Q1 2024. This growth was primarily driven by increased sales of their MRI compatible devices and related services.

Earnings/Net Income

Iradimed's earnings per share (EPS) increased by 12.1% to $0.37 in Q1 2025, compared to $0.33 in Q1 2024. The company's net income also rose by 13.3% to $4.69 million from $4.14 million in the previous year, marking a record high for fiscal Q1 and the highest in 13 years. The EPS growth reflects strong operational performance and profitability.

Price Action

Post-Earnings Price Action Review

Following the earnings announcement, Iradimed's stock price experienced a slight decline, decreasing 2.93% on the latest trading day and 1.36% over the week. Despite the short-term dip, historical data indicates that Iradimed's stock often sees moderate gains post-earnings, with a 3-Day win rate of 40%, a 10-Day win rate of 30%, and a 30-Day win rate of 45%. The maximum observed return was 7.44% over 30 days, suggesting that while price appreciation potential exists, it tends to be modest. The current price action may reflect market volatility or investor caution despite strong earnings.

CEO Commentary

Roger Susi, CEO of Iradimed Corporation, reported a record quarter, marking the 15th consecutive quarter of record revenues with $19.5 million, an 11% increase year-over-year. He highlighted strong performance driven by pump shipments, with the 3860 MRI IV pump bookings excelling. Susi noted ongoing challenges related to tariffs but expressed optimism about managing material costs and supplier pricing. He emphasized the FDA's engagement, indicating that the new 3870 MR IV pump would contribute significantly to revenue in 2026. The CEO conveyed confidence in executing their plans and maintaining positive momentum throughout the year.

Guidance

For Q2 2025, Iradimed expects revenue between $19.7 million and $19.9 million, with GAAP diluted earnings per share projected at $0.37 to $0.40 and non-GAAP diluted earnings per share at $0.41 to $0.44. The company reiterates its full-year 2025 revenue guidance of $78 million to $82 million, anticipating GAAP diluted earnings per share of $1.55 to $1.65 and non-GAAP diluted earnings per share of $1.71 to $1.81.

Additional News

In recent developments, Iradimed Corporation declared a regular quarterly cash dividend of $0.17 per share, payable on May 30, 2025, to shareholders of record as of May 20, 2025. This move reflects the company's commitment to delivering shareholder value and confidence in its financial health. Additionally, Iradimed is on track to complete its new manufacturing facility by July 2025, which is expected to support future growth and operational efficiency. The company continues to focus on expanding its product offerings and maintaining its leadership position in the MRI-compatible medical device market.